Cypherpunk Technologies (NASDAQ:CYPH) Given New $1.60 Price Target at Cantor Fitzgerald

Cypherpunk Technologies (NASDAQ:CYPH) had its target price raised by analysts at Cantor Fitzgerald from $0.90 to $1.60 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 98.66% from the company’s current price.

CYPH has been the subject of several other research reports. Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings raised Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cypherpunk Technologies has an average rating of “Hold” and a consensus price target of $1.60.

Cypherpunk Technologies Price Performance

CYPH stock opened at $0.81 on Wednesday. The firm has a market cap of $86.79 million, a PE ratio of 1.44 and a beta of 0.09. Cypherpunk Technologies has a 12 month low of $0.26 and a 12 month high of $3.70. The firm has a 50 day simple moving average of $0.68 and a 200 day simple moving average of $0.78.

Cypherpunk Technologies (NASDAQ:CYPH) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Cypherpunk Technologies

A number of hedge funds have recently bought and sold shares of CYPH. Simplify Asset Management Inc. bought a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $2,172,000. Acadian Asset Management LLC grew its holdings in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock worth $389,000 after purchasing an additional 1,056,047 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Cypherpunk Technologies during the first quarter valued at approximately $576,000. Geode Capital Management LLC acquired a new position in shares of Cypherpunk Technologies in the fourth quarter valued at $615,000. Finally, State Street Corp acquired a new position in shares of Cypherpunk Technologies in the fourth quarter valued at $163,000. 30.46% of the stock is currently owned by institutional investors.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.